Pacira Pharmaceuticals Stock News

The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital.

-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtu

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q3 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 9.09% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PARSIPPANY, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets o

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the pro

FLXN stock is surging upward today as the company announces a merger with fellow biopharma play Pacira, valuing the company at $450 million. The post FLXN Stock Is Winning Big Today Ahead of Merger Wi

Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share i

Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today anno